Meet our SPARK Fellows

Introducing Cohort 8

Eduardo_Davila_500

Eduardo Davila, PhD

Tumor Infiltrating Lymphocyte Therapy Switch

Tumor Infiltrating Lymphocyte Therapy Switch

The objective of this study is to validate and optimize the use of a synthetic receptor that can selectively expand and differentiate immune cells "on-demand" in cancer patients undergoing cellular therapies. Current treatments involving chemotherapies for preconditioning result in the transient depletion of endogenous T cells and other important immune cells, leading to toxicities and complications. The researchers have developed a synthetic protein that induces T cell proliferation in tissue culture when cross-linked with FDA-approved anti-Her2 antibodies. The study aims to identify the optimal treatment regimen for promoting the proliferation of engineered cells in an in vivo preclinical mouse setting and assess their antitumor activity. Success in this research could lead to significant advancements in cellular therapy, benefiting other treatment areas such as stem cell therapy, infectious diseases, and autoimmunity.

Learn more about Dr. Davila

Cohort 7

Jessica Rove, MD

Jessica Rove, MD

Colorado Chest Tube

Juan-Pablo Idrovo, MD

Juan-Pablo Idrovo, MD

Gastrostomy Tube Guardian

Rui Zhao, PhD

Rui Zhao, PhD

Developing a First-in-Class Allosteric Eya2 Tyrosine Phosphatase Inhibitor for Brain Cancer Therapy

Sujatha Venkataraman, PhD

Development of Gated Dual-antigen Targeting CAR-T Cell Therapy to Treat ATRT, an Aggressive Brain Tumor in Children

zhirui_wang_500

Zhirui Wang, PhD

Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia and Other CD47+ Cancers

Cohort 6

Eduardo_Davila_500

Eduardo Davila, PhD

Tumor Infiltrating Lymphocyte Therapy Switch

Tumor Infiltrating Lymphocyte Therapy Switch

The objective of this study is to validate and optimize the use of a synthetic receptor that can selectively expand and differentiate immune cells "on-demand" in cancer patients undergoing cellular therapies. Current treatments involving chemotherapies for preconditioning result in the transient depletion of endogenous T cells and other important immune cells, leading to toxicities and complications. The researchers have developed a synthetic protein that induces T cell proliferation in tissue culture when cross-linked with FDA-approved anti-Her2 antibodies. The study aims to identify the optimal treatment regimen for promoting the proliferation of engineered cells in an in vivo preclinical mouse setting and assess their antitumor activity. Success in this research could lead to significant advancements in cellular therapy, benefiting other treatment areas such as stem cell therapy, infectious diseases, and autoimmunity.

Learn more about Dr. Davila

Cohort 5

Eduardo_Davila_500

Eduardo Davila, PhD

Tumor Infiltrating Lymphocyte Therapy Switch

Tumor Infiltrating Lymphocyte Therapy Switch

The objective of this study is to validate and optimize the use of a synthetic receptor that can selectively expand and differentiate immune cells "on-demand" in cancer patients undergoing cellular therapies. Current treatments involving chemotherapies for preconditioning result in the transient depletion of endogenous T cells and other important immune cells, leading to toxicities and complications. The researchers have developed a synthetic protein that induces T cell proliferation in tissue culture when cross-linked with FDA-approved anti-Her2 antibodies. The study aims to identify the optimal treatment regimen for promoting the proliferation of engineered cells in an in vivo preclinical mouse setting and assess their antitumor activity. Success in this research could lead to significant advancements in cellular therapy, benefiting other treatment areas such as stem cell therapy, infectious diseases, and autoimmunity.

Learn more about Dr. Davila

Cohort 4

Cohort 3

Cohort 2

Cohort 1

CU Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Mail Stop F411

Aurora, CO 80045


303-724-3720

CMS Login